{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026971","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.854211+00:00","generated_at":"2026-05-17T13:18:25.968121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive","bullets":["Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.","Completed Phase 3 RECOVER OLE 1-year trial: brilaroxazine sustained PANSS total score -18.1 over 1 year.","FDA meeting planned Q4 2025 for path to approval; potential NDA submission targeted Q2 2026.","Completed $10.0M public equity offering in Q2 2025.","Plans to assess registrational Phase 3 RECOVER-2 pending FDA feedback; IND for psoriasis formulation expected Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026971","json":"https://secwatch.observer/filing/0001437749-25-026971.json","markdown":"https://secwatch.observer/filing/0001437749-25-026971.md","text":"https://secwatch.observer/filing/0001437749-25-026971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/0001437749-25-026971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/rvph20250805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:18:25.968121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}